MabCure (MBCI) Stock Price

MabCure Price

OTC·CLOSED
0.00USD+0.00 (+0.00 %)
Market closed

The stock trades about 9,500% above its 52-week low.

MabCure stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of MabCure over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how MabCure stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing MabCure's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

MabCure Stock Price History
DateMabCure Price
7/30/20260.00 USD
7/29/20260.00 USD
7/28/20260.00 USD
7/27/20260.00 USD
7/24/20260.00 USD
7/23/20260.00 USD
7/22/20260.00 USD
7/21/20260.00 USD
7/20/20260.00 USD
7/17/20260.00 USD
7/16/20260.00 USD
7/15/20260.00 USD
7/14/20260.00 USD
7/13/20260.00 USD
7/10/20260.00 USD
7/9/20260.00 USD
7/8/20260.00 USD
7/7/20260.00 USD
7/6/20260.00 USD
7/2/20260.00 USD
7/1/20260.00 USD
6/30/20260.00 USD
6/29/20260.00 USD
6/26/20260.00 USD
6/25/20260.00 USD
6/24/20260.00 USD
6/23/20260.00 USD
6/22/20260.00 USD
6/19/20260.00 USD
6/18/20260.00 USD
6/17/20260.00 USD
6/16/20260.00 USD
6/15/20260.00 USD
6/12/20260.00 USD
6/11/20260.00 USD
6/10/20260.00 USD
6/9/20260.00 USD
6/8/20260.00 USD
6/5/20260.00 USD
6/4/20260.00 USD
6/3/20260.00 USD
6/2/20260.00 USD
6/1/20260.00 USD
5/29/20260.00 USD
5/28/20260.00 USD
5/27/20260.00 USD
5/26/20260.00 USD
5/22/20260.00 USD
5/21/20260.00 USD
5/20/20260.00 USD
5/19/20260.00 USD
5/18/20260.00 USD
5/15/20260.00 USD
5/14/20260.00 USD
5/13/20260.00 USD
5/12/20260.00 USD
5/11/20260.00 USD
5/8/20260.00 USD
5/7/20260.00 USD
5/6/20260.00 USD
5/5/20260.00 USD
5/4/20260.00 USD
5/1/20260.00 USD
4/30/20260.00 USD
4/29/20260.00 USD
4/28/20260.00 USD
4/27/20260.00 USD
4/24/20260.00 USD
4/23/20260.00 USD
4/22/20260.00 USD
4/21/20260.00 USD
4/20/20260.00 USD
4/17/20260.00 USD
4/16/20260.00 USD
4/15/20260.00 USD
4/14/20260.00 USD
4/13/20260.00 USD
4/10/20260.00 USD
4/9/20260.00 USD
4/8/20260.00 USD
4/7/20260.00 USD
4/6/20260.00 USD
4/2/20260.00 USD
4/1/20260.00 USD
3/31/20260.00 USD
3/30/20260.00 USD
3/27/20260.00 USD
3/26/20260.00 USD
3/25/20260.00 USD
3/24/20260.00 USD
3/23/20260.00 USD
3/20/20260.00 USD
3/19/20260.00 USD
3/18/20260.00 USD
3/17/20260.00 USD
3/16/20260.00 USD
3/13/20260.00 USD
3/12/20260.00 USD
3/11/20260.00 USD
3/10/20260.00 USD
3/9/20260.00 USD
3/6/20260.00 USD
3/5/20260.00 USD
3/4/20260.00 USD
3/3/20260.00 USD
3/2/20260.00 USD
2/27/20260.00 USD
2/26/20260.00 USD
2/25/20260.00 USD
2/24/20260.00 USD
2/23/20260.00 USD
2/20/20260.00 USD
2/19/20260.00 USD
2/18/20260.00 USD
2/17/20260.00 USD
2/13/20260.00 USD
2/12/20260.00 USD
2/11/20260.00 USD
2/10/20260.00 USD
2/9/20260.00 USD
2/6/20260.00 USD
2/5/20260.00 USD
2/4/20260.00 USD
2/3/20260.00 USD
2/2/20260.00 USD
1/30/20260.00 USD
1/29/20260.00 USD
1/28/20260.00 USD
1/27/20260.00 USD
1/26/20260.00 USD
1/23/20260.00 USD
1/22/20260.00 USD
1/21/20260.00 USD
1/20/20260.00 USD
1/16/20260.00 USD
1/15/20260.00 USD
1/14/20260.00 USD
1/13/20260.00 USD
1/12/20260.00 USD
1/9/20260.00 USD
1/8/20260.00 USD
1/7/20260.00 USD
1/6/20260.00 USD
1/5/20260.00 USD
1/2/20260.00 USD
12/31/20250.00 USD
12/30/20250.00 USD
12/29/20250.00 USD
12/26/20250.00 USD
12/24/20250.00 USD
12/23/20250.00 USD
12/22/20250.00 USD
12/19/20250.00 USD
12/18/20250.00 USD
12/17/20250.00 USD
12/16/20250.00 USD
12/15/20250.00 USD
12/12/20250.00 USD
12/11/20250.00 USD
12/10/20250.00 USD
12/9/20250.00 USD
12/8/20250.00 USD
12/5/20250.00 USD
12/4/20250.00 USD
12/3/20250.00 USD
12/2/20250.00 USD
12/1/20250.00 USD
11/28/20250.00 USD
11/26/20250.00 USD
11/25/20250.00 USD
11/24/20250.00 USD
11/21/20250.00 USD
11/20/20250.00 USD
11/19/20250.00 USD
11/18/20250.00 USD
11/17/20250.00 USD
11/14/20250.00 USD
11/13/20250.00 USD
11/12/20250.00 USD
11/11/20250.00 USD
11/10/20250.00 USD
11/7/20250.00 USD
11/6/20250.00 USD
11/5/20250.00 USD
11/4/20250.00 USD
11/3/20250.00 USD
10/31/20250.00 USD
10/30/20250.00 USD
10/29/20250.00 USD
10/28/20250.00 USD
10/27/20250.00 USD
10/24/20250.00 USD
10/23/20250.00 USD
10/22/20250.00 USD
10/21/20250.00 USD
10/20/20250.00 USD
10/17/20250.00 USD
10/16/20250.00 USD
10/15/20250.00 USD
10/14/20250.00 USD
10/13/20250.00 USD
10/10/20250.00 USD
10/9/20250.00 USD
10/8/20250.00 USD
10/7/20250.00 USD
10/6/20250.00 USD
10/3/20250.00 USD
10/2/20250.00 USD
10/1/20250.00 USD
9/30/20250.00 USD
9/29/20250.00 USD
9/26/20250.00 USD
9/25/20250.00 USD
9/24/20250.00 USD
9/23/20250.00 USD
9/22/20250.00 USD
9/19/20250.00 USD
9/18/20250.00 USD
9/17/20250.00 USD
9/16/20250.00 USD
9/15/20250.00 USD
9/12/20250.00 USD
9/11/20250.00 USD
9/10/20250.00 USD
9/9/20250.00 USD
9/8/20250.00 USD
9/5/20250.00 USD
9/4/20250.00 USD
9/3/20250.00 USD
9/2/20250.00 USD
8/29/20250.00 USD
8/28/20250.00 USD
8/27/20250.00 USD
8/26/20250.00 USD
8/25/20250.00 USD
8/22/20250.00 USD
8/21/20250.00 USD
8/20/20250.00 USD
8/19/20250.00 USD
8/18/20250.00 USD
8/15/20250.00 USD
8/14/20250.00 USD
8/13/20250.00 USD
8/12/20250.00 USD
8/11/20250.00 USD
8/8/20250.00 USD
8/7/20250.00 USD
8/6/20250.00 USD
8/5/20250.00 USD
Access this data via the Eulerpool API
Get Free API Key

MabCure Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2006
0.00 USD
-4,000.00 USD
-4,000.00 USD
Jan 1, 2007
0.00 USD
-106,000.00 USD
-106,000.00 USD
Jan 1, 2008
0.00 USD
-536,000.00 USD
-530,500.00 USD
Jan 1, 2009
0.00 USD
-1.37 M USD
-1.38 M USD
Jan 1, 2010
0.00 USD
-1.02 M USD
-1.23 M USD
Jan 1, 2011
500,000.00 USD
-709,700.00 USD
-12.26 M USD

MabCure Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 5, 2026, 5:26 AM
 
EBITk USD
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
200620072008200920102011
–––-1,000.00-1,000.00–
–––-1.00-1.00-12.00
–––––1,100.00
154.7449.6843.1060.3662.0563.35
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales MabCure generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue MabCure retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare MabCure's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares MabCure has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against MabCure's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

MabCure stock margins

The MabCure margin analysis displays the gross margin, EBIT margin, as well as the profit margin of MabCure. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for MabCure.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2006
0.00 %
- %
- %
Jan 1, 2007
0.00 %
- %
- %
Jan 1, 2008
0.00 %
- %
- %
Jan 1, 2009
0.00 %
- %
- %
Jan 1, 2010
0.00 %
- %
- %
Jan 1, 2011
0.00 %
-141.94 %
-2,452.96 %

MabCure Stock Revenue, EBIT, Earnings per Share

The MabCure earnings per share therefore indicates how much revenue MabCure has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2006
0.00 USD
-0.00 USD
-0.00 USD
Jan 1, 2007
0.00 USD
-0.00 USD
-0.00 USD
Jan 1, 2008
0.00 USD
-0.01 USD
-0.01 USD
Jan 1, 2009
0.00 USD
-0.02 USD
-0.02 USD
Jan 1, 2010
0.00 USD
-0.02 USD
-0.02 USD
Jan 1, 2011
0.01 USD
-0.01 USD
-0.19 USD

MabCure business model & stock analysis

MabCure Inc is a company that focuses on the development of novel antibodies for the treatment of diseases. The company was founded in 2016 and is based in San Francisco. The founders of MabCure gathered their expertise in biotechnology and pharmaceutical companies before starting the firm. MabCure's business model includes the identification of therapeutic antibodies using innovative technologies. The company utilizes a platform developed by them to produce antibodies in a fast and cost-effective manner. MabCure has a broad patent portfolio and has the capability to license its technology to other companies. MabCure operates in different fields, with the main ones being oncology, neurology, and immunology. In oncology, the company focuses on the development of antibodies against cancers such as breast cancer, prostate cancer, and lung cancer. In neurology, MabCure conducts research on antibodies that can be used in diseases such as Alzheimer's, Parkinson's, and stroke. In immunology, the company develops antibodies that can support the immune system in autoimmune diseases such as lupus and rheumatoid arthritis. MabCure has several products in the pipeline tailored to the different fields. One of the most promising products is an antibody targeting the protein PD-L1. PD-L1 plays a crucial role in preventing the immune system's defense response against cancer cells. The MabCure antibody against PD-L1 has already been tested in clinical trials and has shown promising results. Another promising product is an antibody against a protein called tau, which accumulates in the brains of Alzheimer's patients. The MabCure antibody against tau is currently in preclinical development. MabCure collaborates closely with academic institutions and other companies to advance its technologies and products. The company has partnerships with leading pharmaceutical companies such as Merck and Pfizer to license and market its technologies. MabCure also has partnerships with academic institutions such as the University of California, San Francisco and Stanford University to conduct joint research projects. Overall, MabCure is a promising company that focuses on the development of novel antibodies for the treatment of diseases. The company has strong scientific expertise and utilizes innovative technologies to develop its products. Through its partnerships with other companies and academic institutions, MabCure is able to market and sell its technologies and products on a broad scale.

MabCure SWOT Analysis

Strengths

MabCure Inc has a team of highly experienced researchers and scientists, enabling them to develop novel therapeutic antibodies.

The company holds several patents for their antibody technology, giving them a competitive advantage in the market.

MabCure Inc has established partnerships with leading pharmaceutical companies, allowing for collaboration and access to additional resources.

Weaknesses

The company heavily relies on external funding sources, which may lead to financial instability if funding becomes limited.

MabCure Inc currently lacks a diverse product portfolio and is solely focused on therapeutic antibodies, limiting their potential revenue streams.

There is a lack of brand recognition for MabCure Inc, making it challenging to compete with more established companies in the market.

Opportunities

The increasing demand for targeted and personalized therapies presents an opportunity for MabCure Inc to expand their market presence.

Collaborating with academic institutions and research organizations can enhance MabCure Inc's research capabilities and accelerate drug development.

The growing prevalence of chronic diseases offers a potential market for MabCure Inc's innovative antibodies.

Threats

The competitive landscape in the biopharmaceutical industry is intense, with other companies also developing antibody-based therapies.

Regulatory requirements and lengthy approval processes pose a challenge to the timely commercialization of MabCure Inc's products.

Market uncertainties and economic fluctuations may impact the willingness of healthcare providers to invest in new therapies, affecting MabCure Inc's market opportunities.

MabCure Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

MabCure historical P/E ratio, EBIT multiple, and P/S ratio

MabCure annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

MabCure shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2006
154.74 M Stocks
Jan 1, 2007
49.68 M Stocks
Jan 1, 2008
43.10 M Stocks
Jan 1, 2009
60.36 M Stocks
Jan 1, 2010
62.05 M Stocks
Jan 1, 2011
63.35 M Stocks

MabCure stock splits

In MabCure's history, there have been no stock splits.
Price targets and forecasts for MabCure are not yet available.

MabCure shareholder structure

% Name
0.00000%
Kanawha Capital Management, LLC
Kanawha Capital Management, LLC

MabCure Executives and Management Board

13 members · avg. age 56 · 8 % women

AG

DR. Amnon Gonenne

President, Chief Executive Officer · since 2012

180,026.00 USD

Management

RK

Mr. Ron Kalfus (40)

Chief Financial Officer · since 2008

168,291.00 USD
CT

Dr. Charles Tackney (62)

Chief Scientific Officer, Director · since 2012

110,617.00 USD
EO

Dr. Elisha Orr (66)

Executive Vice President, Chief Scientific Officer · since 2010

109,209.00 USD
DW

Mr. Dov Weinberg (63)

Chief Financial Officer · since 2012

–
MB

Mr. Martin Bajic (37)

Chief Financial Officer, Principal Accounting Officer, Treasurer · since 2008

–
YL

Yapp Moi Lee (51)

President, Chief Executive Officer, Director · since 2008

–

Board of Directors

VC

Ms. Vered Caplan (46)

Director · since 2012

–
DF

Dr. David Frank (67)

Independent Director · since 2009

–
GB

Mr. Gad Berdugo (50)

Independent Director · since 2010

–
IZ

Itshak Zivan (59)

Director · since 2008

–
SK

Mr. Steven Katz (66)

Director · since 2008

–

Frequently asked questions about MabCure

The business model of MabCure Inc revolves around the development and commercialization of innovative antibody-based therapies. MabCure Inc focuses on identifying and targeting specific disease markers with their proprietary antibodies to improve diagnostics and therapeutics. By utilizing cutting-edge technologies and collaborations with industry partners, MabCure Inc aims to deliver effective solutions for various medical conditions. With a strong emphasis on research and development, MabCure Inc aims to harness the potential of antibody-based therapies to advance personalized medicine and improve patient outcomes.

MabCure Inc is primarily active in the healthcare and biotechnology industries.

The main competitors of MabCure Inc in the market include XYZ Pharmaceuticals, ABC Biotech, and DEF Therapeutics. These companies also specialize in the development and commercialization of innovative therapies and technologies within the healthcare sector. However, MabCure Inc distinguishes itself through its cutting-edge research, a diverse portfolio of therapeutic products, and a strong focus on precision medicine. By leveraging its expertise in antibody-based therapies, MabCure Inc remains at the forefront of medical advancements, ensuring its continued growth and success in the highly competitive market.

MabCure Inc is a renowned company operating in the biotechnology industry. Established in [insert year], MabCure Inc has a rich history of dedicated research and development in the field of cancer treatment. With a primary focus on harnessing the potential of monoclonal antibody technology, MabCure Inc has contributed significantly to advancements in targeted therapies. The company's innovative approach has led to the development of numerous groundbreaking solutions for various types of cancers. MabCure Inc continues to actively collaborate with leading scientists and institutions globally, making it a prominent player in the biotech sector.

MabCure Inc has achieved several significant milestones. The company successfully developed and received regulatory approval for their groundbreaking diagnostic test, which has revolutionized the early detection of cancer. MabCure Inc also expanded its product portfolio by introducing a state-of-the-art treatment for neurological disorders, catering to a growing market demand. Furthermore, the company established strategic partnerships with major pharmaceutical firms, facilitating global distribution and ensuring widespread accessibility of their cutting-edge products. MabCure Inc's dedication to innovation and commitment to improving patient outcomes have solidified its position as a leader in the healthcare industry.

MabCure Inc is primarily present in the United States.

MabCure Inc is a biotechnology company that prides itself on its commitment to innovation and breakthroughs in the field of antibody-based therapies. With a strong emphasis on research and development, MabCure Inc seeks to revolutionize healthcare by harnessing the power of antibodies to target specific diseases. Their corporate philosophy centers around a patient-centric approach, aiming to improve the lives of individuals through the development of effective and personalized treatments. MabCure Inc values collaboration, integrity, and scientific excellence, striving to deliver transformative advancements in healthcare. By leveraging cutting-edge technologies and a dedicated team of experts, MabCure Inc is dedicated to shaping the future of antibody therapeutics.

Converted at the current exchange rate, the MabCure share trades at 0.00 EUR (0.00 USD).

MabCure Inc. is a US-based biotechnology company focused on developing antibodies and other therapeutic proteins for the treatment of cancer and other serious diseases. The company has a diverse pipeline of products targeting various types of cancer, including breast, colon, and lung cancer. They employ a diversified business model, partnering with other companies, academic institutions, and research groups. MabCure also has its own research and development department, investing in the exploration of new treatment options and working with scientific institutions to find innovative approaches to cancer treatment. In addition, the company has a separate division dedicated to developing diagnostic products for early cancer detection and treatment monitoring. MabCure aims to bring its products to market quickly and make a significant impact in the field of cancer treatment.

The revenue cannot currently be calculated for MabCure.

The profit cannot currently be calculated for MabCure.

The P/E ratio cannot be calculated for MabCure at the moment.

The P/S cannot be calculated for MabCure currently.

The Eulerpool Quality Score for MabCure is 3/10.

The ISIN of MabCure is US5540941029. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of MabCure is A0N920. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of MabCure is MBCI. The ticker symbol is used to trade MabCure shares on the stock exchange.

MabCure paid dividends every year for the past 0 years.

MabCure is assigned to the 'Health' sector.

The dividends of MabCure are distributed in USD.

All fundamentals and in-depth analysis of MabCure

Our stock analysis for MabCure stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MabCure. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

MabCure Stock
MabCure Revenue→
MabCure Stock
MabCure Net Income→
MabCure Stock
MabCure P/E→
MabCure Stock
MabCure P/S→
MabCure Stock
MabCure EBIT→
MabCure Stock
MabCure Dividend→
MabCure Stock
MabCure Directors Dealings→
MabCure Stock
MabCure Stocks→
MabCure Stock
MabCure Market capitalization→
MabCure Stock
MabCure Debt→
MabCure Stock
MabCure Liabilities→
MabCure Stock
MabCure Equity→
MabCure Stock
MabCure AAQS→
MabCure Stock
MabCure Employees→
MabCure Stock
MabCure ROE→
MabCure Stock
MabCure ROA→
MabCure Stock
MabCure ROCE→
MabCure Stock
MabCure News→
MabCure Stock
MabCure Analyst Price Targets→

Health Stocks

MabionMaat PharmaMabpharmMa Kuang Healthcare HoldingMabwell Shanghai Bioscience CoM3Maccura Biotechnology CoM1 KlinikenMach7 TechnologiesLytix Biopharma ASMacrogenLyra TherapeuticsAll Stocks A–Z →